|
|
Combined impact of bicyclol and probiotics on non-alcoholic fatty liver disease (NAFLD): assessing changes in lipid metabolism and liver function
XU Ying-hong, LING Da-jun, WU Yuan-xiang, LIU Jian
Chinese Hepatolgy
2024, 29 (2):
223-226.
Objective To investigate the effects of bicyclol in combination with probiotics on non-alcoholic fatty liver disease (NAFLD) and to evaluate its influence on lipid metabolism and liver function. Methods Between June 2019 and June 2022, a total of 102 patients diagnosed with NAFLD were enrolled at our hospital. These patients were randomly divided into two groups, with each group comprising 51 individuals: an observation group and a control group. Bicyclol were administered to the control group, while the observation group received a combination treatment consisting of bicyclol and bifidobacterium-triplex viable capsules. Liver function and lipid metabolism indicators were evaluated before and after treatment.The clinical efficacy and safety profiles of the two therapeutic strategies were compared. Results The study revealed that the total effective rates for the obersvation and control groups were 90.2% and 74.5%, respectively, with the observation group showing a significantly higher rate (P<0.05). Post-treatment, serum aspartate aminotransferase (AST) levels were measured at (49.2±11.5) U/L for the observation group and (65.3±11.8) U/L for the control group. Similarly, alanine aminotransferase (ALT) levels were(50.8±13.2) U/L and (68.2±12.7) U/L, repectively. Glutamyl transpeptidase (GGT) levels also followed this trend, being(48.5±9.8) U/L in the observation group and (61.2±10.3) U/L in the control group(P<0.05). Furthermore, triglyceride (TG) levels were (1.8±0.4) mmol/L, and total cholesterol (TC) levels were (4.3±0.6) mmol/Lin the observation group, compared to (5.1±0.8) mmol/L in the control group. Low-density lipoprotein cholesterol (LDL-C) levels were also lower in the observation group at (2.6±0.5) mmol/L, compared to (3.5±0.7) mmol/L in the control group, with a significant difference(P<0.05). High-density lipoprotein cholesterol (HDL-C) levels were (1.6±0.4) mmol/L in the observation group and (1.3±0.4) mmol/L in the contrl group, with the observation group showing higher levels(P<0.05). Following treatment, the observation group exhibited a higher serum HDL-C level(P<0.05). Additionally, post-treatment assessments revealed that the counts of enterococcus and Escherichia coli in the observation group, recorded at (4.9±1.2) lgCFU/g and (6.2±0.9) lgCFU/g respectively, were significantly lower compared to the control group, which showed counts of [(6.6±1.0) lgCFU/g and (6.9±1.2) lgCFU/g, respectively(P<0.05). Conversely, the abundance of Bifidobacterium and Lactobacillus in the observation group, measured at (7.5±1.1) lgCFU/g and (6.8±1.3) lgCFU/g respectively, was significantly higher than in the control group. Which had counts of (6.7±1.1) lgCFU/g and (5.9±0.9) lgCFU/g(P<0.05). Post-treatment adverse reactions were observed in 9 cases (17.6%) within the observation group, including fatigure(3 cases, 5.9%), loss of appetite(4 cases, 7.8%), and insomnia(2 cases, 3.9%). In the control group 5 cases (9.80%) experienced adverse reactions, including fatigue(1 case, 2.0%), loss of appetite(2 cases, 3.9%), and insomnia(2 cases, 3.9%). The difference in adverse reactions between the two groups was not statistically significant(P>0.05). Conclusion The application of bicyclol in combination with probiotics for treating patients with NAFLD appears beneficial in mitigating intestinal flora imbalances, regulating lipid levels, and improving liver function. This treatment approach also demonstrates good safety profiles, suggesting its potential value for wider clinical adoption.
Reference |
Related Articles |
Metrics
|
|
